Serum low-density lipoprotein cholesterol level is strong risk factor for acquired color vision impairment in young to middle-aged Japanese men: The Okubo Color Study Report 2

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 542-547

  Shoji, Takuhei ^a,b   Sakurai, Yutaka ^b   Sato, Hiroki ^b   Chihara, Etsuo ^c   Ishida, Masahiro ^b   Omae, Kazuyuki ^a  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Sensho kai Eye Institute   (Japan)

Author keywords

Acquired color vision impairment; Cardiovascular risk factors; Low density lipoprotein cholesterol; Prevalence

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLOR VISION DEFECT; COLOR VISION TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EYE EXAMINATION; HIGH RISK PATIENT; HUMAN; INTERVIEW; JAPANESE; LIPID METABOLISM; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; ALCOHOL DRINKING; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CATARACT; CHOLESTEROL, LDL; COLOR VISION; COLOR VISION DEFECTS; CROSS-SECTIONAL STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; RISK FACTORS; SMOKING;

EID: 77953232794     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.11.039     Document Type: Article

References (29)

1. Third Report of the National Cholesterol Education Panel (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel or ATP III). NIH Publication No. 01-3305, May 2001.
2. Casserly I., Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004, 363:1139-1146. Review.
3. Hofman A., Ott A., Breteler M.M., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
4. Luchsinger J.A., Reitz C., Honig L.S., et al. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005, 65:545-551.
5. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 2004, 41:7-10. Review.
6. Triviño A., Ramírez A.I., Salazar J.J., et al. A cholesterol-enriched diet induces ultrastructural changes in retinal and macroglial rabbit cells. Exp Eye Res 2006, 83:357-366.
7. Melamud A., Hagstrom S., Traboulsi E. Color vision testing. Ophthalmic Genet 2004, 25:159-187. Review.
8. Gobba F. Related color vision: a sensitive indicator of exposure to neurotoxins. Neurotoxicology 2000, 21:857-862. Review.
9. Gobba F., Cavalleri A. Color vision impairment in workers exposed to neurotoxic chemicals. Neurotoxicology 2003, 24:693-702. Review.
10. Vu B.L., Easterbrook M., Hovis J.K. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999, 106:1799-1803.
11. Fong D.S., Barton F.B., Bresnick G.H. Impaired color vision associated with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 15. Am J Ophthalmol 1999, 128:612-617.
12. Pacheco-Cutillas M., Edgar D.F., Sahraie A. Acquired colour vision defects in glaucoma-their detection and clinical significance. Br J Ophthalmol 1999, 83:1396-1402. Review.
13. Bimler D., Kirkland J. Multidimensional scaling of D15 caps: color-vision defects among tobacco smokers?. Vis Neurosci 2004, 21:445-448.
14. Hiratsuka Y., Li G. Alcohol and eye diseases: a review of epidemiologic studies. J Stud Alcohol 2001, 62:397-402. Review.
15. Cheung N., Wong T.Y. Obesity and eye diseases. Surv. Ophthalmol 2007, 52:180-195. Review.
16. Shoji T., Sakurai Y., Chihara E., et al. Reference intervals and discrimination values of the Lanthony desaturated D-15 panel test in young to middle-aged Japanese army officials: the Okubo Color Study Report 1. Eye 2009, 23:1329-1335.
17. Verriest G., Van Laethem J., Uvijls A. A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores. Am J Ophthalmol 1982, 93:635-642.
18. American Diabetes Association Standards of medical care in diabetes. Diab Care 2006, (Suppl. 1):S4-S42.
19. James P.T., Leach R., Kalamara E., et al. The worldwide obesity epidemic. Obes Res 2001, (Suppl. 4):228S-233S. Review.
20. Chylack L.T., Wolfe J.K., Singer D.M., et al. The Lens Opacities Classification System. III. The longitudinal study of cataract study group. Arch Ophthalmol 1993, 111:831-836.
21. Taylor H.R., West S.K. A simple system for the clinical grading of lens opacities. Lens Res 1988, 5:175-181.
22. van Leeuwen R., Klaver C.C., Vingerling J.R., et al. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol 2003, 121:519-526.
23. Alcalá A., Morell M., Rius F. Chromatic computerized analysis is an early predictor of cardiovascular risk associated to hypercholesterolemia. Rev Esp Cardiol 2001, 54:1417-1425.
24. Alcalá A., Jansen S., Farkouh M.E., et al. Hypercholesterolemia is associated with visual field alterations detectable with computerized perimetry. Atherosclerosis 2007, 195:e167-e171.
25. Ong J.M., Zorapapel N.C., Rich K.A., et al. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest Ophthalmol Vis Sci 2001, 42:1891-1900.
26. Bretillon L., Acar N., Seeliger M.W., et al. ApoB100, LDLR-/- mice exhibit reduced electroretinographic response and cholesteryl esters deposits in the retina. Invest Ophthalmol Vis Sci 2008, 49:1307-1314.
27. Hinton D.R., Sadun A.A., Blanks J.C., et al. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 1986, 315:485-487.
28. Katz B., Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 1989, 34:31-43. Review.
29. Woo G.C. Are ethnic differences in the F-M 100 scores related to macular pigmentation?. Clin Exp Optom 2002, 85:372-377.